Ruxolitinib as an emerging treatment in myelofibrosis
Robyn M Emanuel,1 Holly L Geyer,1 Ruben A Mesa2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA Abstract: Essential thrombocythemia, polycythemia vera, and myelofibrosis belong to the class of Bcr-Abl negative hematologic neoplasms, which ar...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-03-01
|
| Series: | Blood and Lymphatic Cancer: Targets and Therapy |
| Online Access: | http://www.dovepress.com/ruxolitinib-as-an-emerging-treatment-in-myelofibrosis-a12419 |